The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
Open accessAbstract
Abstract Background Incretin-based therapies are used in the treatment of type 2 diabetes mellitus (T2DM) and obesity. We investigated the changes in arterial stiffness and left ventricular (LV) myocardial deformation after 6-month treatment with the GLP-1 analogue liraglutide in subjects with newly diagnosed T2DM. Methods We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months. We measured at baseline and after 6-month treatment: (a) carotid-femoral pulse wave velocity (PWV) (b) LV longitudinal strain (GLS), and strain rate (GLSR), peak twisting (pTw), peak twisting velocity (pTwVel) and peak untwisting velocity (pUtwVel) using speckle tracking echocardiography. LV untwisting was calculated as the percentage difference between peak twisting and untwisting at MVO (%dpTw–UtwMVO), at peak (%dpTw–UtwPEF) and end of early LV diastolic filling (%dpTw–UtwEDF) (c) Flow mediated dilatation (FMD) of the brachial artery and percentage difference of FMD (FMD%) (d) malondialdehyde (MDA), protein carbonyls (PCs) and NT-proBNP. Results After 6-months treatment, subjects that received liraglutide presented with a reduced PWV (11.8 ± 2.5 vs. 10.3 ± 3.3 m/s), MDA (0.92 [0.45–2.45] vs. 0.68 [0.43–2.08] nM/L) and NT-proBNP (p < 0.05) in parallel with an increase in GLS (− 15.4 ± 3 vs. − 16.6 ± 2.7), GLSR (0.77 ± 0.2 vs. 0.89 ± 0.2), pUtwVel (− 97 ± 49 vs. − 112 ± 52°, p < 0.05), %dpTw–UtwMVO (31 ± 10 vs. 40 ± 14), %dpTw–UtwPEF (43 ± 19 vs. 53 ± 22) and FMD% (8.9 ± 3 vs. 13.2 ± 6, p < 0.01). There were no statistically significant differences of the measured markers in subjects that received metformin except for an improvement in FMD. In all subjects, PCs levels at baseline were negatively related to the difference of GLS (r = − 0.53) post-treatment and the difference of MDA was associated with the difference of PWV (r = 0.52) (p < 0.05 for all associations) after 6-month treatment. Conclusions Six-month treatment with liraglutide improves arterial stiffness, LV myocardial strain, LV twisting and untwisting and NT-proBNP by reducing oxidative stress in subjects with newly diagnosed T2DM. ClinicalTrials.gov Identifier NCT03010683
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, evidence for oxidative stress markers like MDA is promising but varied, with some trials showing clear superiority of GLP-1 RAs over insulin or metformin (9, 21, 22).”
In the citing paper
“In mechanistic studies, GLP-1RAs were shown to improve cardiac function in patients with T2DM.”
From The cardioprotective effects of semaglutide exceed those of dietary weight loss in mice with HFpEF (2023) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ESH/ESC Guidelines for the management of arterial hypertension
Authors Task Force Members, Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Böhm, M., Christiaens, T., Cífková, R., Backer, G. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,728
Lang, R. M., Badano, L. P., Mor-Avi, V., Afilalo, J., Armstrong, A., Ernande, L., Flachskampf, F. A., Foster, E., Goldstein, S. A., Kuznetsova, T., et al. (2015) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2014.10.003 · Cited by 12,362
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Lang, R. M., Badano, L. P., Mor‐Avi, V., Afilalo, J., Armstrong, A. D. C., Ernande, L., Flachskampf, F. A., Foster, E., Goldstein, S. A., Kuznetsova, T., et al. (2015) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jev014 · Cited by 8,583
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
[49] Determination of carbonyl content in oxidatively modified proteins
Levine, R. L., Garland, D. L., Oliver, C. N., Amici, A., Climent, I., Lenz, A.-G., Ahn, B. W., Shaltiel, S., & Stadtman, E. R. (1990) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(90)86141-h · Cited by 5,895
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Diabetes, oxidative stress, and antioxidants: A review
Maritim, A. C., Sanders, R. A., & Watkins, J. B. (2003) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.10058 · Cited by 3,167
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Authors Task Force Members, Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,987
Cited by
Sorted by citations
Items 101–146 of 146
Peppa, M., Pavlidis, G., Mavroeidi, I., Katogiannis, K., Varoudi, M., Thymis, J., Kostelli, G., Vlastos, D., Plotas, P., Bamias, A., et al. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002903 · Cited by 7
Self-citationMasarone, D., Valente, F., Verrengia, M., Contaldi, C., Palma, V. D., Falco, L., Catapano, D., & di Lorenzo, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226867 · Cited by 7
Larsson, M., Patrone, C., von Euler, M., Holst, J. J., & Nathanson, D. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0896-z · Cited by 7
Role of endogenous GLP ‐1 on arterial stiffness and renal haemodynamics following bariatric surgery
Moriconi, D., Bruno, R. M., Rebelos, E., Armenia, S., Baldi, S., Bonvicini, L., Taddei, S., & Nannipieri, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14256 · Cited by 6
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Sundararaman, L. V., Gouda, D., Kumar, A., Sundararaman, S., & Goudra, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14061978 · Cited by 7
Usefulness of Arterial Stiffness as an Integrated Marker of Cardiovascular Risk
Prado, G., Forner, M. J., Calaforra, O., Vela, S., Serrano, C. B., Pichler, G., Gracia, A. D., Navarro, L. S., Rodilla, E., Redón, J., et al. (2025) · Journal of Clinical Hypertension · doi:10.1111/jch.70038 · Cited by 5
Zhang, H., Leng, S., Gao, F., Kovalik, J., Tan, R., Wee, H. N., Chua, K. V., Ching, J., Zhao, X., Allen, J. C., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01127-x · Cited by 5
Liu, Y., Tseng, Y., Wu, Y.-H., Tong, L., Tsai, S., Huang, S., Wu, B., Lo, S., Chen, I.-C., Dai, Z., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177106 · Cited by 5
Bock, J. M., Hughes, W. E., Ueda, K., Feider, A. J., Hanada, S., & Casey, D. P. (2021) · Physiological Reports · doi:10.14814/phy2.14764 · Cited by 5
GLP‐1: A Prospective Guardian for Comprehensive Myocardial Perfusion
Li, Z., Yu, Y., Li, J., Jiang, X., Chen, J., Ye, N., Wu, B., Sun, Y., & Sun, G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70004 · Cited by 4
Zhong, Z., Chen, K., Zhao, Y., & Xia, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/9993229 · Cited by 4
Afrăsânie, I., Matei, I. T., Leancă, S. A., Chetran, A., Costache, A. D., Afrăsânie, V.-A., Dmour, B.-A., Crișu, D., Bădescu, M. C., Șerban, L., et al. (2023) · Life · doi:10.3390/life13020443 · Cited by 4
Arévalo‐Lorido, J. C., Carretero‐Gómez, J., Huelgas, R. G., López, R. Q., Ramos, M. F. D., Serrado-Iglesias, A., Ruiz-Laiglesia, F., Franco, Á. G., Rodrigo, J. M. C., & Montero-Pérez-Barquero, M. (2020) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2019.10.008 · Cited by 4
Effect of Liraglutide on Cardiac Function in Individuals With Type 2 Diabetes: A Meta-Analysis
Haroon, H., Kumari, A., Lal, B., Kumari, A., Kumar, J., Khreis, K., Sheikh, M., & Amin, A. (2023) · Cureus · doi:10.7759/cureus.42651 · Cited by 4
Kanbay, M., Shah, E., AlShiab, R., Ozbek, L., Ay, S., Rustamov, A., Covic, A., Mallamaci, F., & Zoccali, C. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.71106 · Cited by 4
Goodman, J. A., Schain, M., Stefano, G. D., Lupson, V. C., Horn, T., Hill, M., Manavaki, R., Fryer, T. D., Bumanlag-Amis, E., Jalaludeen, N., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-04559-3 · Cited by 5
Lu, Z., Ma, G., & Chen, L. (2020) · Mediators of Inflammation · doi:10.1155/2020/8143835 · Cited by 3
Nodari, S., Fioretti, F., & Barillà, F. (2022) · Heart Failure Reviews · doi:10.1007/s10741-021-10203-9 · Cited by 3
Arévalo‐Lorido, J. C., Carretero‐Gómez, J., Huelgas, R. G., López, R. Q., Ramos, M. F. D., Serrado-Iglesias, A., Ruiz-Laiglesia, F., Franco, Á. G., Rodrigo, J. C., Montero-Pérez-Barquero, M., et al. (2020) · Revista Clínica Española · doi:10.1016/j.rce.2019.10.001 · Cited by 3
Alrasheed, T., Mostafa, M. E. A., Madkhali, M. A., & Khairy, H. A. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1734549 · Cited by 4
Fountoulakis, N., Pavlou, P., Stathi, D., Goubar, A., Corcillo, A., Flaquer, M., Ayis, S. A., Gnudi, L., & Karalliedde, J. J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70481 · Cited by 2
Detection of subclinical heart failure
Thavendiranathan, P., & Negishi, K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-75947-2.00011-8 · Cited by 2
Rol de nuevos fármacos antidiabéticos en prevención cardiovascular e insuficiencia cardiaca
Rojas-Velázquez, J. M., Giralt-Herrera, A., Leiva-Enríquez, J., & Leiva-Enríquez, J. (2021) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2021.02.013 · Cited by 1
The Conventional and Alternative Therapeutic Approaches in Arterial Stiffness Management
Randriamboavonjy, J. I., Conti, V., Mazza, I., Ragot, T., Andrianjara, C., Rafatro, H., & Tesse, A. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18020166 · Cited by 1
Xanthopoulou, M., Evangelidis, P., Poulis, D., Gavriilaki, E., Kotsiou, N., Antza, C., Kotsis, V., Doxani, C., Mprotsis, T., Zintzaras, E., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19030462 · Cited by 2
Role of newer antidiabetic drugs on cardiovascular prevention and heart failure
Rojas-Velázquez, J. M., Giralt-Herrera, A., Leiva-Enríquez, J., & Leiva-Enríquez, J. (2021) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2021.11.002 · Cited by 1
Akyay, Ö. Z., Sahin, T., Çakmak, Y., Tarkun, İ., Selek, A., Cantürk, Z., Çetinarslan, B., & Karakaya, D. (2022) · Nigerian Journal of Clinical Practice · doi:10.4103/njcp.njcp_1640_21 · Cited by 2
GLP1-Receptor Agonists in Diabetes: Drugs, General Effects, and Cardiovascular Impact
Breder, I. S. S., & Sposito, A. C. (2020) · Springer eBooks · doi:10.1007/978-3-030-53370-0_51 · Cited by 1
Beneficial effects of liraglutide on peripheral blood vessels
Zhang, X., Wang, Y., Yang, S., Zong, J., Wang, X., & Bai, R. (2020) · Vojnosanitetski pregled · doi:10.2298/vsp200423089z
Tamura, H., Kondo, Y., Ito, K., Hasebe, M., Satoh, S., & Terauchi, Y. (2019) · Research Square · doi:10.21203/rs.2.14604/v1
Tamura, H., Kondo, Y., Ito, K., Hasebe, M., Satoh, S., & Terauchi, Y. (2020) · Research Square · doi:10.21203/rs.2.14604/v5
Tamura, H., Kondo, Y., Ito, K., Hasebe, M., Satoh, S., & Terauchi, Y. (2020) · Research Square · doi:10.21203/rs.2.14604/v4
Tamura, H., Kondo, Y., Ito, K., Hasebe, M., Satoh, S., & Terauchi, Y. (2019) · Research Square · doi:10.21203/rs.2.14604/v2
Tamura, H., Kondo, Y., Ito, K., Hasebe, M., Satoh, S., & Terauchi, Y. (2019) · Research Square · doi:10.21203/rs.2.14604/v3
Zorampari, C., Gupta, R., & Gupta, L. K. (2023) · European Medical Journal · doi:10.33590/emj/10306493
Clinical Implications of Ventricular-Arterial Coupling and the Role of Therapeutic Interventions
Ikonomidis, I., Pavlidis, G., & Vlastos, D. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00005-2
Self-citationRandriamboavonjy, J. I., Rafatro, H., & Andrianjara, C. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4865304
Weningtyas, A., Hose, V. A. G., Ramadhiani, R., Rohman, M. S., Nugrahenny, D., & Rudijanto, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113057
Ferdinand, K. C., Dunn, J., Nicolay, C., Sam, F., Blue, E. K., & Wang, H. (2023) · Figshare · doi:10.6084/m9.figshare.22624691
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Figshare · doi:10.6084/m9.figshare.16696428
Simeone, P., Tripaldi, R., Michelsen, A. E., Ueland, T., Liani, R., Ciotti, S., Birkeland, K. I., Gulseth, H. L., Di Castelnuovo, A., Cipollone, F., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19350000
锁, 晓. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.1662277
Pagel, P. S., Hang, D., Freed, J. K., & Crystal, G. J. (2026) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2026.07.030
GLP-1 as a Regulator of Oxidative Signalling in Metabolic Health and Disease
Kurhaluk, N., Kołodziejska, R., & Ткаченко, Г. М. (2026) · Antioxidants · doi:10.3390/antiox15101283
Shengning, G. A. O., Shan, Y., Ma, D., Zhou, X., & Gao, W. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1921737
Fazli, Z., & Pooranachandran, V. (2026) · Echocardiography · doi:10.1111/echo.70657
Metadata
- Authors
- Lambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., Lekakis, J., Iliodromitis, E., Dimitriadis, G., & Ikonomidis, I.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Corresponding author
- Lambadiari, Vaia
- ORCID
- Venue
- Cardiovascular Diabetology
- Published
- 2018-01-08
- Volume
- 17
- Issue
- 1
- Pages
- 8-8
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC5759220
- OpenAlex
- W2782989965
- Cited by
- 146
- References
- 52
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 18 · 2023: 16 · 2022: 17 · 2021: 22 · 2020: 21 · 2019: 22 · 2018: 7
- FWCI
- 14.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Diabetology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Keywords
- liraglutide, GLP-1 receptor agonists, type 2 diabetes, newly diagnosed diabetes, arterial stiffness, left ventricular myocardial deformation, oxidative stress, metformin, pulse wave velocity, flow-mediated dilation, malondialdehyde, protein carbonyls, NT-proBNP, speckle tracking echocardiography
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adult, Biomechanical Phenomena, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Female, Greece, Humans, Hypoglycemic Agents, Male, Middle Aged, Myocardial Contraction, Peptide Fragments, Time Factors, Biomarkers, Ventricular Function, Left, Treatment Outcome, Oxidative Stress, Natriuretic Peptide, Brain, Incretins, Diabetic Cardiomyopathies, Vascular Stiffness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
